Sars-cov-2 (covid-19) mrna-lnp vaccine (cvx 309) Side Effects
Applies to sars-cov-2 (covid-19) mrna-lnp vaccine (cvx 309): intramuscular suspension.
Warning
Becoming infected with COVID-19 is much more dangerous to your health than receiving this vaccine.
Get emergency medical help if you have signs of an allergic reaction: hives, difficult breathing, swelling of your face, lips, tongue, or throat.
Your vaccination provider may want to watch you for a short time after your shot, to make sure you don't have an allergic reaction. You will be treated quickly if you have a reaction right after you receive the vaccine.
You should not receive this vaccine if the first shot of COVID-19 vaccine caused an allergic reaction. Your doctor or vaccination provider will determine if you can safely receive this vaccine.
Not all possible side effects are known. Becoming infected with COVID-19 is much more dangerous to your health than receiving this vaccine.
Some people receiving this vaccine had inflammation of the heart muscle or the lining around the heart within the first week after receiving this vaccine, but the risk of this side effect is very low. Seek medical attention right away if you have:
-
chest pain;
-
fast or pounding heartbeats or fluttering in your chest.
Common side effects may include:
-
fever, chills;
-
pain, bruising, swelling, or irritation where the shot was given;
-
feeling tired; or
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects.
You may also use a smartphone-based program called V-safe to communicate with the Centers for Disease Control and Prevention (CDC) about any health problems you have after receiving a COVID-19 vaccine: www.cdc.gov/vsafe.
For Healthcare Professionals
Applies to sars-cov-2 (covid-19) mrna-lnp vaccine (cvx 309): intramuscular suspension.
General
The most commonly reported side effects included injection site pain, fatigue, and headache.[Ref]
Cardiovascular
Postmarketing reports: Myocarditis, pericarditis[Ref]
Dermatologic
Frequency not reported: Hyperhidrosis, night sweats
Postmarketing reports: Pruritus, rash, urticaria[Ref]
Gastrointestinal
Very common (10% or more): Diarrhea (up to 10.7%)
Common (1% to 10%): Vomiting
Frequency not reported: Nausea[Ref]
Hematologic
Common (1% to 10%): Lymphadenopathy[Ref]
Hypersensitivity
Postmarketing reports: Anaphylaxis, angioedema, other hypersensitivity reactions (e.g., pruritus, rash, urticaria), severe allergic reactions[Ref]
Local
Very common (10% or more): Injection site pain (up to 90.5%), injection site swelling (up to 10.6%), injection site redness (up to 10.4%)
Postmarketing reports: Extremity (arm) pain[Ref]
Metabolic
Frequency not reported: Decreased appetite[Ref]
Musculoskeletal
Very common (10% or more): Chills (up to 49.2%), muscle pain (up to 45.5%), new/worsened muscle pain (up to 39.3%), joint pain (up to 27.5%), new/worsened joint pain (up to 23.8%)[Ref]
Nervous system
Very common (10% or more): Headache (up to 75.5%)
Frequency not reported: Lethargy
Postmarketing reports: Dizziness, syncope[Ref]
Other
Very common (10% or more): Fatigue (up to 77.5%), use of antipyretic or pain medication (up to 50.8%), fever (up to 24.3%)
Frequency not reported: Asthenia, malaise[Ref]
More about sars-cov-2 (covid-19) mrna-lnp vaccine (cvx 309)
Patient resources
Other brands
Comirnaty (2023-2024) PF (cvx 309)
Related treatment guides
References
1. Product Information. Comirnaty (2023-2024) PF (cvx 309) (SARS-CoV-2 (COVID-19) mRNA-LNP vaccine (cvx 309)). Pfizer U.S. Pharmaceuticals Group. 2023.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Some side effects may not be reported. You may report them to the FDA.